We use AI to empower scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug.
From target identification through to clinical development, our AI-enabled Benevolent Platform™ augments scientific ingenuity, with the goal of improving the probability of clinical success.
BenevolentAI has a rich drug pipeline that mixes both potentially best-in-class and first-in-class drug candidates, all entirely generated using the Benevolent Platform™.
We partner with leading pharmaceutical and biotech companies to tackle therapeutic challenges from new angles and develop novel drugs for complex multifactorial diseases.
Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.
News and media
Get the latest news and updates from BenevolentAI on our AI-driven drug and research programmes, collaborations, investments and events.
Join us to work on a mission that matters: uniting AI and cutting-edge science to discover and develop new medicines for complex diseases.